Webinar - SMID-Cap Biotech & Pharma and ESG
Updated: Jun 3, 2019
Why is now the time for small- and mid-cap biotech & pharma executives, directors, IROs and legal teams to learn more about the “Environmental, Social and Governance” (ESG) landscape, where to start and how best to communicate to investors?
Given the rapid rise of interest in the topic by institutional investors and other company stakeholders, senior management teams and corporate directors increasingly need to take a proactive approach with their companies’ ESG policies and messaging. This is the case even if your shareholders and analysts have never asked you questions about ESG factors or your ESG ratings.
Join ESG industry leaders for a conversation that’s specific to biotech & pharma:
• Introduction to ESG
• Investor engagement on ESG
• ESG and SMID-cap biotech & pharma
• Tips for effective ESG planning
• Industry examples
